Nerve ablation, also called radiofrequency ablation, is a procedure that helps relieve chronic pain—one of the most ...

NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.

NeuroOne filed its FDA 510(k) for trigeminal nerve ablation months ahead of its revised May 2025 timeline. OneRF system targets trigeminal neuralgia, a condition impacting ~100K in the U.S., using ...

The submission was completed earlier than anticipated, noted the company. The OneRF Trigeminal Nerve Ablation System features a minimally invasive, temperature-controlled RF procedure that uses a ...

The submission and potential FDA clearance may lead to revenue generation from the trigeminal nerve ablation market, enhancing the company's financial outlook for late 2025. This press release ...